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783 
To assess the efficacy and toxicity of chemotherapy for advanced germ cel tumorsぅ115patients 
with testicular and extragonadal germ cell tumors were reviewed. Five-year survival rates of 19 
seminoma patients and 96 non-seminoma patients were 84% and 68%ラrespectively. Accordirig to the 
analysis using three sets of prognostic criteriaう IndianaUniversity ClassificationラInternationalGerm 
Cell Consensus Classification and K Classificationラthe5-year survival rate of poor-prognosis patients 
was 42-45%. BEP regimen (bleomycinぅ etoposideand cisplatin) salvaged with VIP (etoposideぅ
ifosfamide and cisplatin) would be the standard therapy for advanced germ cell tumors since high-dose 
chemotherapy had no advantage on survival over the standard同doseregimen. Early serious toxicities 
were observed in 18 patients (15.7%)ラ includingpulmonary fibrosis， respiratory distressう andsepsis. 
Poor performance status and prior radiotherapy were risk factors for fatal adverse effects. In terms of 
late toxicites， out of 76 patients in complete remission for at least one year after cessation of 
chemotherapyぅ 31had numbness of extremities and 29 had tinnitus. Serial semen analyses of 38 
patients showed continuous azoospermia or severe oligozoospermia in 22. These data indicated that 
less toxic therapy was required for good問riskpatients to improve the quality oflifeラwhilemore intensive 
therapy for poor側riskpatients to be cured. Several prognostic criteria should be utilized to properly 
distinguish good-from poor田riskpatientsラ anddecide how to treat each patient. 
(Acta Urol. Jpn. 45: 783-786ラ 1999)

































し， 1979年の cisplatinの導入当時は PVB6)で，そ
の後1983年からは VAB67)で導入化学療法を行うよ
うになり，残存腫療に癌細胞を認めた場合や再発症例


























































67.7 96 83.6 19 Total 
Prognostic classification and survival 
ofnorトsemllloma
Table 2. 



























Induction chemotherapy and survival 
of non-seminoma 
Table 3. 
% poor-prognosis 5-year 
survival 
rate (%) 












































IND: Indiana U ni竹ve白r討t吋y Classi迅五cation凡1，IGCCC う
International Germ Cell Consensus Classi泊岳cationう K; 
K Classification. 
果議吉










セミノーマ 19例の病期は IIA(6例)， IIB (6)， 
IIIA (4)， IIIBl (1)， IIIC (2)，非セミノーマ96例
の病期は IIA(14例)， IIB (16)， IIIA (19)， IIIBl 
(10)， IIIB2 (27)， IIIC (10)であった.全症例の観

















例の bleomycinの使用総量は 270mgが3例， 360 
mg， 450 mgが各 l例であった.ただし臨床上明らか
であったものは 3例で 残りの 2例は姉摘除の標本あ
るいは剖検によって明らかになったものである.死亡
した 8例の performancestatusは， 0; 2例
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